Publication | Open Access

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy

OncologyGastrointestinal OncologyMedicineLong-term Follow-up ResultsClinical TrialsPharmacotherapyCancer TreatmentPharmacologyRadiation OncologyHealth Sciences